研究者詳細 - 増子　正義

論文 - 増子　正義

分割表示 129 件中 41 - 60 件目／全件表示 >>

A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. 査読国際誌

Tetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, Shinichi Masuda, Yasuhiko Shibasaki, Tatsunori Goto, Noriko Fukuhara, Nobuharu Fujii, Kazuhiro Ikegame, Junichi Sugita, Takashi Ikeda, Yachiyo Kuwatsuka, Ritsuro Suzuki, Yuho Najima, Noriko Doki, Tomonori Kato, Yuichiro Inagaki, Yoshikazu Utsu, Nobuyuki Aotsuka, Masayoshi Masuko, Seitaro Terakura, Yasushi Onishi, Yoshinobu Maeda, Masaya Okada, Takanori Teshima, Makoto Murata

Annals of hematology 100 ( 3 ) 743 - 752 2021年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 107/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0-85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 109/L on day 60 was 80.6% (68.2-88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L on day 100 were 75.8% (62.6-84.9%) and 72.6% (59.4-82.1%), respectively, with median time to platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.

DOI： 10.1007/s00277-020-04365-z

PubMed

researchmap

Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse-risk AML patients. 査読国際誌

Kyoko Fuse, Tomoyuki Tanaka, Yasuhiko Shibasaki, Tatsuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

European journal of haematology 105 ( 5 ) 616 - 625 2020年11月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Chromosome analysis is necessary for the risk classification of acute myeloid leukemia (AML). Marker chromosome (MC) is a fragmented chromosome whose origin cannot be identified from other chromosomes and originates from marked genomic instability. Although AML with MC (MC+) has a poor prognosis even after intensive chemotherapy, its influence on the outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. OBJECTIVE AND METHODS: We retrospectively analyzed 162 AML patients after allo-HSCT. To evaluate the significance of MC, we compared it with other chromosomal abnormalities. RESULT: Marker chromosome was detected in 14 (8.6%, MC+) patients (vs MC-, n = 158). The 2-year overall survival (OS) in MC+ vs MC- was 26.8% vs 62.2% (P = .0098). The 2-year cumulative incidence of relapse (CIR) in MC+ vs MC- was 80.4% vs 35.5% (P = .0004). Among adverse-risk AML (AD-AML, n = 36), AD-AML/MC+ (n = 11) demonstrated a poorer 2-year OS (9.1%, vs AD-AML/MC- n = 25, 58.3%, P = .0031) and higher 2-year CIR (89.6%, vs AD-AML/MC- 44.7%, P = .002). In multivariate analysis, MC (HR 3.08, 95% CI; 1.02-9.29, P = .046) and HCT-CI (HR 3.23, 95% CI; 1.00-10.4, P = .049) were independent risk factors for CIR among AD-AML. CONCLUSION: Our study suggests MC as a new independent factor for chromosome risk classification to further classify AD-AML.

DOI： 10.1111/ejh.13495

PubMed

researchmap

Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. 査読国際誌

Shohei Mizuno, Masamitsu Yanada, Koji Kawamura, Masayoshi Masuko, Naoyuki Uchida, Yukiyasu Ozawa, Koji Iwato, Kazuteru Ohashi, Kazuhiro Ikegame, Sung-Won Kim, Masatsugu Tanaka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shingo Yano, Akiyoshi Takami

Bone marrow transplantation 56 ( 1 ) 232 - 242 2020年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) confers a dismal prognosis when treated with chemotherapy alone. Data on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes are limited. We retrospectively analyzed 4649 AML patients who received allo-HCT and were in complete remission. Outcomes of Ph+ AML (n = 30), intermediate-risk, and poor-risk AML patients were compared. The 3-year overall survival after allo-HCT was similar in intermediate-risk (62.7%; 95% CI: 61.0-64.3%) and Ph+ AML (73.3%; 95% CI: 51.5-86.4%) groups (P = 0.42); however, it differed significantly between the poor-risk (49.7%; 95% CI: 45.9-53.4%) and Ph+ AML (73.3%; 95% CI: 51.5-86.4%) groups (P = 0.049). Disease-free survival in Ph+ AML patients was comparable to that in intermediate-risk patients but better than that in poor-risk patients. Relapse rates were significantly lower in Ph+ AML patients than in other groups. Non-relapse mortality (NRM) rates were similar among groups. Multivariate analysis showed that Ph+ AML was not a significant predictor of poor prognosis in terms of overall survival, disease-free survival, relapse, and NRM. Our data showed better post-transplant outcomes for Ph+ AML patients than for those with poor-risk AML. Hence, allo-HCT could be a feasible treatment option for Ph+ AML patients.

DOI： 10.1038/s41409-020-01011-0

PubMed

researchmap

Hypertrophic pachymeningitis associated with myelodysplastic syndrome

Akane Kaihatsu, Kyoko Fuse, Hirohito Sone, Masayoshi Masuko

eJHaem 1 ( 1 ) 12 - 13 2020年7月

The Glasgow prognostic score divides high-risk hematopoietic cell transplantation-specific comorbidity index patients into stratified subgroups in allogeneic hematopoietic cell transplantation. 査読国際誌

Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Kyoko Fuse, Miwako Narita, Hirohito Sone, Masayoshi Masuko

Annals of hematology 99 ( 3 ) 671 - 673 2020年3月

Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. 査読国際誌

Masamitsu Yanada, Takaaki Konuma, Satoshi Yamasaki, Yachiyo Kuwatsuka, Masayoshi Masuko, Masatsugu Tanaka, Yukiyasu Ozawa, Takashi Toya, Takahiro Fukuda, Shuichi Ota, Masashi Sawa, Naoyuki Uchida, Hirohisa Nakamae, Tetsuya Eto, Junya Kanda, Minoko Takanashi, Yoshinobu Kanda, Yoshiko Atsuta, Shingo Yano

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 26 ( 2 ) 307 - 315 2020年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

This study aimed to investigate time-varying effects of graft type on outcomes for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant. For this purpose we analyzed 3952 patients, 720 of whom underwent matched related bone marrow transplantation (BMT), 1004 matched related peripheral blood stem cell transplantation (PBSCT), 856 matched unrelated BMT, and 1372 umbilical cord blood transplantation (UCBT) during complete remission. The 4-year relapse-free survival (RFS) rates were 59.1%, 52.8%, 59.5%, and 50.6%, respectively. Compared with related BMT, related PBSCT, unrelated BMT, and UCBT were associated with higher risk of nonrelapse mortality and unrelated BMT and UCBT with lower risk of relapse. As a result, both RFS and overall survival were comparable between related BMT and unrelated BMT but were worse for related PBSCT and UCBT than for related BMT. Adverse impact of UCBT was observed only during the early phase of transplant, whereas that of related PBSCT continued even after 2 years post-transplant. Our findings raise concerns about the increased risk of late nonrelapse mortality with the use of PBSC grafts and suggest that related BMT is preferable to related PBSCT; matched unrelated BMT is the next choice in the absence of a matched related donor.

DOI： 10.1016/j.bbmt.2019.09.036

PubMed

researchmap

Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. 査読国際誌

Masahiro Uemura, Masato Kanazawa, Takuma Yamagishi, Takahiro Nagai, Mami Takahashi, Shingo Koide, Masayoshi Tada, Junsuke Shimbo, Aiko Isami, Kunihiko Makino, Masayoshi Masuko, Kouji Nikkuni, Kouichirou Okamoto, Shuichi Igarashi, Kenichi Morita, Osamu Onodera

Journal of the neurological sciences 408 116577 - 116577 2020年1月

Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. 査読国際誌

Yasuyuki Arai, Tadakazu Kondo, Kyoko Fuse, Yasuhiko Shibasaki, Masayoshi Masuko, Junichi Sugita, Takanori Teshima, Naoyuki Uchida, Takahiro Fukuda, Kazuhiko Kakihana, Yukiyasu Ozawa, Tetsuya Eto, Masatsugu Tanaka, Kazuhiro Ikegame, Takehiko Mori, Koji Iwato, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta

Blood advances 3 ( 22 ) 3626 - 3634 2019年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Acute graft-versus-host disease (aGVHD) is 1 of the critical complications that often occurs following allogeneic hematopoietic stem cell transplantation (HSCT). Thus far, various types of prediction scores have been created using statistical calculations. The primary objective of this study was to establish and validate the machine learning-dependent index for predicting aGVHD. This was a retrospective cohort study that involved analyzing databases of adult HSCT patients in Japan. The alternating decision tree (ADTree) machine learning algorithm was applied to develop models using the training cohort (70%). The ADTree algorithm was confirmed using the hazard model on data from the validation cohort (30%). Data from 26 695 HSCT patients transplanted from allogeneic donors between 1992 and 2016 were included in this study. The cumulative incidence of aGVHD was 42.8%. Of >40 variables considered, 15 were adapted into a model for aGVHD prediction. The model was tested in the validation cohort, and the incidence of aGVHD was clearly stratified according to the categorized ADTree scores; the cumulative incidence of aGVHD was 29.0% for low risk and 58.7% for high risk (hazard ratio, 2.57). Predicting scores for aGVHD also demonstrated the link between the risk of development aGVHD and overall survival after HSCT. The machine learning algorithms produced clinically reasonable and robust risk stratification scores. The relatively high reproducibility and low impacts from the interactions among the variables indicate that the ADTree algorithm, along with the other data-mining approaches, may provide tools for establishing risk score.

DOI： 10.1182/bloodadvances.2019000934

PubMed

researchmap

Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation. 査読国際誌

Masao Ogata, Naoyuki Uchida, Takahiro Fukuda, Kazuhiro Ikegame, Tomohiko Kamimura, Makoto Onizuka, Koji Kato, Hikaru Kobayashi, Yoji Sasahara, Masashi Sawa, Akihisa Sawada, Daiichiro Hasegawa, Masayoshi Masuko, Toshihiro Miyamoto, Shinichiro Okamoto

Bone marrow transplantation 55 ( 6 ) 1004 - 1013 2019年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Reactivation of human herpesvirus (HHV)-6B is relatively common after allogeneic hematopoietic stem cell transplantation (HSCT) and HHV-6B diseases may consequently develop. Among them, HHV-6B encephalitis is a serious and often fatal complication. The aim of these clinical practice recommendations is to provide diagnostic and therapeutic guidance for HHV-6B encephalitis after allogeneic HSCT. In this evidence-based review, we critically evaluated data from the published literature. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assist in generating recommendations. We have summarized the findings that contribute to decision-making and we have provided our recommendations. In cases where rigorous clinical data are unavailable, recommendations have been developed in discussions with physicians who have relevant expertize.

DOI： 10.1038/s41409-019-0752-5

PubMed

researchmap

骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

海發茜, 小堺貴司, 田村秀, 片桐隆幸, 河本啓介, 難波亜矢子, 布施香子, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

臨床血液 60 ( 10 ) 1503 - 1503 2019年10月

Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. 査読国際誌

Yanada M, Mori J, Aoki J, Masuko M, Harada K, Uchida N, Doki N, Fukuda T, Sakura T, Kanamori H, Sawa M, Kondo T, Katayama Y, Kanda J, Ichinohe T, Atsuta Y, Yano S

Annals of hematology 98 ( 9 ) 2179 - 2186 2019年9月

Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. 査読国際誌

Fuse K, Uemura S, Tamura S, Suwabe T, Katagiri T, Tanaka T, Ushiki T, Shibasaki Y, Sato N, Yano T, Kuroha T, Hashimoto S, Furukawa T, Narita M, Sone H, Masuko M

Cancer medicine 8 ( 11 ) 5058 - 5067 2019年9月

Rhnull phenotype caused by a novel RHAG mutation, c.945+1G>A, in the Japanese population. 査読国際誌

Ushiki T, Tsuneyama H, Masuko M, Kozakai T, Kasami T, Tanaka T, Uchikawa M, Kitajima T, Kasai E, Komata T, Katagiri T, Kamimura M, Sato K, Fuse I, Ogasawara K, Nakata K

Transfusion 59 ( 8 ) 2519 - 2522 2019年8月

Hodgkin lymphomaとAnaplastic large cell lymphomaの鑑別が困難であった巨大縦隔腫瘤を呈した1例

河本啓介, 鈴木隆晴, 海發茜, 田村秀, 片桐隆之, 難波亜矢子, 布施香子, 柴崎康彦, 増子正義, 曽根博仁, 三好寛明, 大島孝一, 瀧澤淳

日本リンパ網内系学会会誌 59 133 - 133 2019年5月

Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. 査読国際誌

Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Nakamae H, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S

Bone marrow transplantation 54 ( 4 ) 578 - 586 2019年4月

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. 査読

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Tamura S, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

Internal medicine (Tokyo, Japan) 58 ( 4 ) 575 - 580 2019年2月

Anaplastic large cell lymphoma, with 1,25(OH)2D3-mediated hypercalcemia: A case report. 査読

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

Journal of clinical and experimental hematopathology : JCEH 59 ( 1 ) 22 - 28 2019年

Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. 査読

Tamura S, Kawamoto K, Miyoshi H, Suzuki T, Katagiri T, Kasami T, Nemoto H, Miyakoshi S, Kobayashi H, Shibasaki Y, Masuko M, Takeuchi K, Ohshima K, Sone H, Takizawa J

Journal of clinical and experimental hematopathology : JCEH 58 ( 4 ) 161 - 165 2018年12月

急性骨髄性白血病に対する同種造血幹細胞移植成績の過去20年間の変遷(Trends in survival of AML patients undergoing related and unrelated HCT during the past two decades)

柳田正光, 増子正義, 森甚一, 青木淳, 水野昌平, 福田隆浩, 垣花和彦, 小澤幸泰, 太田秀一, 金森平和, 森毅彦, 中前博久, 衛藤徹也, 白鳥聡一, 前田哲生, 岩戸康治, 一戸辰夫, 神田善伸, 田中淳司, 熱田由子, 矢野真吾

臨床血液 59 ( 9 ) 1485 - 1485 2018年9月

同種造血細胞移植における移植前リスク評価に用いられるGlasgow予後予測スコアの改良(Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation)

Shibasaki Yasuhiko, Suwabe Tatsuya, Katagiri Takayuki, Tanaka Tomoyuki, Ushiki Takashi, Fuse Kyoko, Sato Naoko, Yano Toshio, Kuroha Takashi, Hashimoto Shigeo, Narita Miwako, Furukawa Tatsuo, Sone Hirohito, Masuko Masayoshi

International Journal of Hematology 108 ( 3 ) 282 - 289 2018年9月

記述言語：英語出版者・発行元：(一社)日本血液学会

同種造血細胞移植(HCT)の移植前リスク評価に用いられるGlasgow予後予測スコア(GPS)に改良を加え、その有用性について検討した。同種HCTを施行された血液疾患患者205例(中央値46歳)を対象とした。HCT特異的GPS(HCT-GPS)の評価に際して、CRP上昇(1mg/dL超)、低アルブミン血症(3.5g/dL未満)の両者を満たす場合は2点、いずれかを呈する場合は1点、いずれも認めない場合は0点とし、さらに血清中フェリチン1000ng/mL超を呈する場合には+1点とした。検討の結果、移植前の血清フェリチン中央値は954ng/mL、アルブミン中央値は4.1g/dL、CRP中央値は0.14mg/dLであり、HCT-GPSスコアは0点が95例、1点が75例、2点が19例、3点が16例であった。一方、オリジナルのGPSスコアでは0点が158例、1点が28例、2点が19例であった。C統計量分析では非再燃死亡率(NRM)と全生存率(OS)はHCT-GPSスコアの方がGPSスコアより高値であったが有意差は認められなかった。一方、net reclassification indexesとintegrated discrimination improvementを用いた解析では有意差がみられた。また、多変量解析ではHCT-GPSスコアの1点増分はOSとNRMの不良を示す独立予測因子であることが示された。今回作成したHCT-GPSスコアは同種HCT後の早期合併症の予測に有用なツールに成りうると思われた。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J04671&link_issn=&doc_id=20181129310007&doc_link_id=10.1007%2Fs12185-018-2463-x&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs12185-018-2463-x&type=Crossref&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00002_2.gif

　前のページ - 次のページ　

<増子 正義>

論文 - 増子 正義

<増子　正義>

論文 - 増子　正義